Canaccord analyst Gary Nachman last night initiated coverage of Scholar Rock (SRRK) with a Buy rating and $62 price target The company’s lead product apitegromab is nearing approval and launch later this year, the analyst tells investors in a research note. The firm says this “key catalyst has been meaningfully derisked” as it relates to manufacturing following the recent application resubmission. It sees blockbuster potential for apitegromab in spinal muscular atrophy.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRRK:
- Scholar Rock initiated with a Buy at Canaccord
- Scholar Rock price target raised to $57 from $54 at Jefferies
- De-Risked Regulatory Path and Manufacturing Readiness Underpin Buy Rating on Apitegromab
- Morning News Wrap-Up 3/31/26: Today’s Biggest Stock Market Stories!
- Scholar Rock price target raised to $58 from $51 at BofA